null

VivoGenie SARS-CoV-2 Spike NTD [2215] Low Endotoxin Antibody (IVMB0239)

SKU:
IVMB0239
Antibody Type:
In Vivo Biosimilar
Endotoxin Level:
Low Endotoxin
Applications:
In Vivo
Disease Area:
Cancer
Clone:
2215
Protein:
SARS-CoV-2 Spike NTD
Synonyms:
COV2-2215, SARS-CoV2 Spike NTD, COVID-19, 2019-nCoV, Severe acute respiratory syndrome coronavirus 2, SARS-CoV2
Isotype:
Human IgG1
Reactivity:
Virus
€409 - €739

Description

system_update_altDatasheet
Product Name:Anti-SARS-CoV-2 Spike NTD [2215]
Product Code:IVMB0239
Clone:2215
Protein:SARS-CoV-2 Spike NTD
Product Type:Recombinant Monoclonal Antibody
Synonyms:COV2-2215, SARS-CoV2 Spike NTD, COVID-19, 2019-nCoV, Severe acute respiratory syndrome coronavirus 2, SARS-CoV2
Isotype:Human IgG1
Reactivity:SARS-CoV-2 ? Virus
Immunogen:Sequenced from human survivors of COVID-19 (SARS-CoV-2)
Applications:ELISA
Formulation:This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Endotoxin Level:< 1.0 EU/mg as determined by the LAL method
Purity:≥95% monomer by analytical SEC
Storage and Handling:This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Applications:ELISA
Recommended Usage:ELISA
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Reactivity:SARS-CoV-2 ? Virus
Specificity:Anti-SARS-CoV-2 Spike NTD, clone 2215, specifically targets an epitope on the SARS-CoV-2 spike protein N-terminal domain.
Antigen Distribution:The spike NTD is expressed on the surface of SARS-CoV-2.
Immunogen:Sequenced from human survivors of COVID-19 (SARS-CoV-2)
Concentration:≥ 5.0 mg/ml
Endotoxin Level:< 1.0 EU/mg as determined by the LAL method
Purity:≥95% monomer by analytical SEC
Formulation:This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Storage and Handling:This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus that belongs to the Coronaviridae family 1. The SARS-CoV-2 genome, which shares 79.6% identity with SARS-CoV, encodes four essential structural proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid protein (N) 2. The S protein is a transmembrane, homotrimeric, class I fusion glycoprotein that mediates viral attachment, fusion, and entry into host cells 3. Each ~180 kDa monomer contains two functional subunits, S1 (~700 a.a) and S2 (~600 a.a), that mediate viral attachment and membrane fusion, respectively. S1 contains two major domains, the N-terminal (NTD) and C-terminal domains (CTD). In both SARS-CoV and SARS-CoV-2, the CTD contains the receptor-binding domain (RBD), which binds to the angiotensin-converting enzyme 2 (ACE2) receptor on host cells3-5. The NTD of SARS-CoV-2 does not bind to ACE26, and the function of NTD in SARS-CoV-2 infection is not well understood. In other CoVs, the NTD may promote attachment by binding to sugar moieties7 and might play a role in the conformational change of S2 required for membrane fusion8. While most neutralizing antibodies target the RBD domain and block receptor binding, potent neutralizing antibodies targeting NTD were isolated from convalescent COVID19 patients9, identifying the NTD as an attractive candidate for vaccines and therapeutics. In addition, the NTD is a promising antigen for diagnostic tests, as there is only 53.5% homology between the NTD of SARS-CoV-2 and SARS-CoV10.
Protein:SARS-CoV-2 Spike NTD
Research Area:COVID-19, Viral

Related Products